论文部分内容阅读
新近应用DNA重组技术生产的人干扰素,为研究高纯α干扰素的抗肿瘤效能提供了机会。 45例患者均经组织学证实为非何杰金氏淋巴瘤(NHL)。男女比率3:2,中位年龄44岁。大多数患者虽然最初用单剂或联合化疗有效,但在拟用干扰素的已对第二或第三线联合化疗无反应。患者用肌注重组白细胞A干扰素治疗,剂量50×10~6u/M~2,每周3次。治疗首日预先口服扑热息痛600mg,4小时1次,以后发热时服用。患者出现不能耐受的疲倦、厌
The recent application of recombinant human interferon DNA technology, for the study of high-purity interferon alpha antitumor efficacy provides the opportunity. All 45 patients were histologically confirmed as non-Hodgkin’s lymphoma (NHL). Male to female ratio of 3: 2, the median age of 44 years old. Although most patients are initially treated with a single agent or combination of chemotherapy, the second or third line of combination chemotherapy is not responding to interferon. Patients with intramuscular injection of leukocyte interferon A treatment, a dose of 50 × 10 ~ 6u / M ~ 2, 3 times a week. The first day of treatment, oral paracetamol 600mg, 4 hours 1, after taking fever. Patients can not tolerate the tired, tired